Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on News From Europe!.
Press releases published on July 18, 2025
Digital Transformation Europe Returns to Amsterdam – The Premier Enterprise Tech Event of the Year
EIN Presswire
·
July 18, 2025
AMSTERDAM, NETHERLANDS, July 18, 2025 /EINPresswire.com/ -- Digital Transformation Expo Europe, part of TechEx Europe, one of Europe’s largest enterprise technology events, is back in Amsterdam this September. Taking place at the RAI Amsterdam on 24–25 …
Wealth Legacy Feng Shui Planning Explains the Key Element Missing in Luxury Home Design
EIN Presswire
·
July 18, 2025
HONG KONG, HONG KONG, July 18, 2025 /EINPresswire.com/ -- A survey of Hong Kong’s most exclusive luxury neighborhoods reveals that 90% of ultra-high-net-worth families (assets exceeding HKD 100 million) share the same hidden Feng Shui code—while your …
Ditto Transcripts Unveils Surging General Transcription Services Market: 99% Accuracy & Compliant Human‑Powered
EIN Presswire
·
July 18, 2025
Ditto Transcripts reports rapid growth in general transcription, highlighting unmatched 99% accuracy, compliance, and trusted U.S.-based human transcriptionists DENVER, CO, UNITED STATES, July 17, 2025 /EINPresswire.com/ -- Ditto Transcripts, a trusted …
SAPU Bioscience Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients
GlobeNewswire
·
July 18, 2025
Data supports further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma. SAN DIEGO, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Sapu Biosciences, LLC (Sapu), a wholly owned …
Successful Commercial Launch of Ryoncil®
GlobeNewswire
·
July 18, 2025
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales of Ryoncil® (remestemcel-L-rknd) through the first …